亞 盛 醫 藥
Ascentage Pharma

ASCENTAGE PHARMA GROUP INTERNATIONAL
亞盛醫藥集團

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 6855)

Voluntary Announcement

Ascentage Pharma to Present Latest Clinical Data of Bcl-2 Inhibitor Lisaftoclax (APG-2575) in Patients with Relapsed/Refractory Non-Hodgkin Lymphomas at 2022 European Hematology Association Hybrid Congress

Ascentage Pharma Group International (the "**Company**" or "**Ascentage Pharma**") is pleased to announce that it will release the latest results from a Phase I clinical study of lisaftoclax (APG-2575), the novel type I Bcl-2 selective inhibitor under the development of the Company, in Chinese patients with relapsed/refractory non-Hodgkin lymphomas (r/r NHLs) at the 2022 European Hematology Association Hybrid Congress (EHA 2022), making it the Company's first appearance at the EHA Congress.

The EHA Congress is the largest gathering of the hematology field in Europe. It showcases most cutting-edge research and state-of-the-art innovative therapies, attracting over 10,000 clinical experts and researchers from over 100 countries every year. This year, the EHA Congress will take place both online and in-person in Vienna, Austria, from June 9, 2022 to June 12, 2022.

Preliminary Results of a Phase 1 Study of Novel Bcl-2 Inhibitor Lisaftoclax (APG-2575) in Chinese Patients (pts) with Relapsed or Refractory (r/r) Non-Hodgkin Lymphomas (NHLs)

- Abstract number: P1106
- Session title: Indolent and mantle-cell non-Hodgkin lymphoma — Clinical
- Date and Time of Report: Friday, June 10, 2022, 16:30-17:45 (CET)

APG-2575 is a novel, orally administered small-molecule Bcl-2 selective inhibitor being developed by Ascentage Pharma to treat hematologic malignancies and solid tumors by selectively blocking the antiapoptotic protein Bcl-2 and hence restoring the normal apoptosis process in cancer cells. APG-2575 is the first China-developed Bcl-2 inhibitor entering clinical development in China, and the second entering pivotal studies globally. APG-2575 is being studied in multiple clinical studies in countries and regions including the China, the US, Australia, and Europe, for a range of solid tumors and hematologic malignancies such as CLL/SLL.

About Ascentage Pharma

Ascentage Pharma is a China-based, globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, CHB (Chronic hepatitis B), and age-related diseases. On October 28, 2019, Ascentage Pharma became listed on the Main Board of The Stock Exchange of Hong Kong Limited with the stock code: 6855.HK.

Ascentage Pharma has its own platform for developing therapeutics that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Company has built a pipeline of eight type I small molecule clinical drug candidates which have entered the clinical development stage, including novel, highly potent Bcl-2, and dual Bcl-2/Bcl-xL inhibitors, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors (TKIs). Ascentage Pharma is also the only company in the world with active clinical programs targeting all three known classes of key apoptosis regulators. The Company is conducting more than 50 Phase I/II clinical trials in China, the US, Australia and Europe. Olverembatinib, the Company's core drug candidate developed for the treatment of drug-resistant chronic myeloid leukemia (CML), was granted Priority Review status and a Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA), and is already approved for the indication. In addition, Olverembatinib has also been granted an Orphan Drug Designation (ODD) and a Fast Track Designation (FTD) by the US FDA, and an Orphan Designation by the EU. As at the date of this announcement, Ascentage Pharma has obtained a total of 15 ODDs from the US FDA and 1 ODD from the EU for four of the Company's investigational drug candidates. The Company has been designated for multiple major national R&D projects in China, including five Major New Drug Development Projects, one Enterprise Innovative Drug Incubator Base status, four Innovative Drug Research and Development Programs, and one Major Project for the Prevention and Treatment of Infectious Diseases.

Leveraging its robust research and development capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights, and entered into global partnerships with numerous leading biotechnology and pharmaceutical companies and research institutes such as UNITY Biotechnology, MD Anderson Cancer Center, Mayo Clinic, Dana-Farber Cancer Institute, MSD, AstraZeneca and Pfizer. The Company has built a global and talented team with experience in the research and development of innovative drugs and clinical development, and is setting up its commercial manufacturing and sales and marketing teams with high standards. Ascentage Pharma aims to continuously strengthen its research and development capabilities and accelerate the clinical development progress of its product pipeline to fulfil its mission of 'addressing unmet clinical needs of patients in China and around the world' for the benefit of more patients.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: We cannot guarantee that we will be able to obtain further approval for, or ultimately market, APG-2575 successfully.

By order of the Board
Ascentage Pharma Group International
Dr. Yang Dajun
Chairman and Executive Director

Suzhou, People's Republic of China, May 23, 2022

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Yang Dajun as Chairman and executive Director, Dr. Wang Shaomeng and Dr. Lu Simon Dazhong as non-executive Directors, and Mr. Ye Changqing, Dr. Yin Zheng, Mr. Ren Wei and Dr. David Sidransky as independent non-executive Directors.